Kivizidiale

Timolol and Travoprost, the active ingredients in Kivizidiale, are a beta‑blocker and a prostaglandin analog presented as eye drops for ocular use. The combination lowers intra‑ocular pressure and is indicated for primary open‑angle glaucoma and ocular hypertension in adult patients.\n\nGNH India supplies Kivizidiale as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Kivizidiale combines a beta‑blocker and a prostaglandin analog to lower intra‑ocular pressure in glaucoma‑related conditions.\n\n- Primary open‑angle glaucoma: reduces intra‑ocular pressure to slow optic nerve damage.\n- Ocular hypertension: lowers eye pressure to prevent progression to glaucoma.\n- Secondary open‑angle glaucoma: helps control pressure when other treatments are insufficient.

Kivizidiale may cause ocular and systemic adverse reactions.\n\nCommon Side Effects:\n- Eye irritation or burning sensation\n- Blurred vision\n- Redness of the eye\n- Dry eye or foreign‑body sensation\n- Itching or mild eyelid swelling\n- Temporary changes in eye color (increased brown pigmentation)\n\nSerious or Rare Side Effects:\n- Severe allergic reaction (rash, swelling, difficulty breathing)\n- Worsening of glaucoma or sudden rise in intra‑ocular pressure\n- Chest pain, bradycardia, or systemic hypotension\n- Respiratory distress in asthmatic patients\n- Persistent eye pain or vision loss\n- Corneal ulceration or infection

Before prescribing Kivizidiale, clinicians should consider patient‑specific factors and monitor for adverse events.\n\n- Cardiovascular assessment: beta‑blocker component may cause bradycardia or hypotension.\n- Respiratory status: avoid in patients with asthma or severe chronic obstructive pulmonary disease.\n- Intra‑ocular pressure monitoring: adjust therapy based on regular pressure measurements.\n- Concomitant ocular beta‑blockers: avoid duplicate therapy to reduce systemic exposure.\n- Pregnancy and lactation: use only if potential benefit justifies potential risk to the fetus or infant.\n- Store at room temperature: keep in the original container, protect from light and moisture.

Kivizidiale can interact with systemic and ocular medications; awareness of potential interactions helps ensure safety.\n\nMajor Interactions (Avoid):\n- Systemic beta‑blockers (e.g., metoprolol): additive bradycardia or hypotension.\n- Other prostaglandin analog eye drops: increased risk of ocular irritation and hyperpigmentation.\n- Monoamine oxidase inhibitors: possible cardiovascular effects when combined with beta‑blocker.\n\nModerate Interactions (Monitor Closely):\n- Anticholinergic eye drops: may reduce the IOP‑lowering efficacy of timolol.\n- Topical corticosteroids: can diminish overall pressure‑lowering effect.\n- Non‑steroidal anti‑inflammatory eye drops: may increase ocular irritation when used together.